Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
Dyne Therapeutics, Inc. director Edward Hurwitz received a grant of stock options as part of his compensation. The award covers 35,152 stock options, each exercisable for one share of common stock at an exercise price of $17.04 per share. According to the disclosure, these options were granted on June 5, 2026 and will vest in full on the earlier of June 5, 2027 or the company’s 2027 Annual Meeting of Stockholders, provided he continues in service. Following this grant, Hurwitz holds 35,152 derivative securities from this award.
Dyne Therapeutics director David Charles Lubner received a new stock option grant covering 35,152 shares of common stock. The option has an exercise price of $17.04 per share and expires on June 4, 2036. All 35,152 underlying shares are scheduled to vest in full on the earlier of June 5, 2027 or the company’s 2027 Annual Meeting of Stockholders, subject to his continued service. After this grant, Lubner holds 35,152 stock options directly. This is a compensation-related award rather than an open-market purchase or sale.
Dyne Therapeutics director Jason P. Rhodes received a grant of stock options for 35,152 shares of common stock. The options have an exercise price of $17.04 per share and expire on June 4, 2036. The shares underlying the option are scheduled to vest in full on the earlier of June 5, 2027 or the company’s 2027 annual stockholder meeting, subject to continued service. Rhodes is obligated to transfer any economic benefit from shares issued on exercise to Atlas Venture Life Science Advisors, and he disclaims beneficial ownership except for any pecuniary interest.
Dyne Therapeutics director Dirk Kersten received a new stock option grant as part of his compensation. On June 5, 2026, he was awarded options covering 35,152 shares of common stock at an exercise price of $17.04 per share.
The option vests in full on the earlier of June 5, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as Kersten continues to serve the company. After this grant, he holds 35,152 stock options directly, and there are no additional derivative holdings shown in this filing.
Dyne Therapeutics, Inc. director Carlo Incerti received a grant of stock options on June 5, 2026. The award covers 35,152 options to purchase Common Stock at an exercise price of $17.04 per share, held directly.
The options expire on June 4, 2036 and are scheduled to vest in full on the earlier of June 5, 2027 or the date of Dyne Therapeutics’ 2027 Annual Meeting of Stockholders, provided Incerti continues in service. Following this grant, he holds 35,152 derivative securities linked to common shares.
Dyne Therapeutics director Catherine Stehman-Breen received a new stock option grant as part of her compensation. On June 5, 2026 she was awarded options to purchase 35,152 shares of Dyne Therapeutics common stock at an exercise price of $17.04 per share.
The option vests in full on the earlier of June 5, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as she continues to serve. Following this grant, she holds 35,152 stock options directly under this award, which expire on June 4, 2036.
Dyne Therapeutics director Brian S. Posner reported two insider transactions. He made an open-market purchase of 2,000 shares of common stock at $16.94 per share, bringing his directly held stake to 24,500 shares.
He also received a grant of stock options covering 35,152 shares of common stock with an exercise price of $17.04 per share. According to the disclosure, these options vest in full on the earlier of June 5, 2027 or the date of Dyne Therapeutics’ 2027 annual stockholders’ meeting, subject to his continued service.
Dyne Therapeutics, Inc. reported results from its 2026 annual stockholder meeting. Stockholders elected David Lubner, Brian Posner and Jason Rhodes as Class III directors to serve three-year terms ending at the 2029 annual meeting.
Stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers and ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. They also approved an amendment to increase authorized common shares from 200,000,000 to 400,000,000 and a separate amendment providing for officer exculpation, with both amendments effected by certificates of amendment filed on June 8, 2026.
Dyne Therapeutics, Inc. director Brian S. Posner reported an open-market purchase of Common Stock. On June 3, 2026, he bought 2,500 shares at $17.48 per share. After this transaction, his directly held position increased to 22,500 shares of Dyne Therapeutics common stock.
Dyne Therapeutics announced completion of enrollment in the registrational expansion cohort of its Phase 1/2 ACHIEVE trial of z‑basivarsen for myotonic dystrophy type 1. The cohort includes 71 participants, providing the main data set to support potential regulatory submissions.
The company plans topline data from this cohort in the first quarter of 2027, aiming to use these results, along with multiple ascending dose and long‑term extension data, for a potential Biologics License Application seeking U.S. Accelerated Approval in the third quarter of 2027. Dyne anticipates a potential U.S. launch in the first half of 2028 if Priority Review is granted and approval is received, and it is also pursuing approval pathways outside the U.S.